Want to see CAI full AI Analyst Report?
CAI Stock Chart & Stats
$28.01
-$0.13(-0.83%)
At close: 4:00 PM EDT
$28.01
-$0.13(-0.83%)
Day’s Range― - ―
52-Week Range$14.19 - $33.65
Previous CloseN/A
Volume4.93M
Average Volume (3M)5.02M
Market Cap
$7.77B
Enterprise Value$4.70B
Total Cash (Recent Filing)$793.12M
Total Debt (Recent Filing)$452.40M
Price to Earnings (P/E)79.8
Beta2.20
Next Earnings
Nov 11, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend Yield2.06%
Share Statistics
EPS (TTM)0.37
Shares Outstanding282,595,180
10 Day Avg. Volume4,168,323
30 Day Avg. Volume5,021,188
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)13.19
Price to Sales (P/S)9.38
P/FCF Ratio113.87
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit6.82
Enterprise Value/Ebitda27.22
Forecast
1Y Price Target
$28.33Price Target Upside1.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)0.12
Revenue Forecast (FY)$1.03B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Raised GuidanceRapid revenue growth, rising molecular-profiling demand, and higher full-year guidance indicate expanding adoption of Caris’s oncology services. If clinical volume and pricing gains persist, the larger revenue base can support continued investment in testing capacity, product development, and commercial reach over the next several quarters.
Improving Margins And Cash GenerationThe combination of materially higher gross margin, positive adjusted EBITDA, and consecutive quarters of positive free cash flow marks an important operating improvement. Sustained cash generation would strengthen internal funding capacity and reduce reliance on external financing while the company scales its diagnostic portfolio.
Proprietary Data And Expanding Diagnostic PlatformA large profiled-patient dataset with outcomes can reinforce Caris’s precision-oncology capabilities and support AI-enabled clinical and biopharma offerings. New products and broader clinician adoption expand the platform’s use cases, potentially creating durable differentiation across diagnostics and research services.
Bears Say
Persistent GAAP LossesDespite improved EBITDA and cash flow, the company remains far from consistent GAAP profitability after several years of substantial losses. Continued net losses can constrain retained capital, reduce confidence in earnings quality, and make durable profitability dependent on further margin expansion and disciplined expense control.
MCED Reimbursement And Evidence UncertaintyCaris Detect and the MRD program could broaden the company’s opportunity, but reimbursement and regulatory pathways remain unresolved. Delayed coverage decisions or additional evidence requirements could slow adoption, limit near-term revenue contribution, and increase the time and investment needed to commercialize these products.
Capacity And Operating Execution RiskScaling laboratory capacity quickly enough to meet demand is a material execution challenge. Backorders or delays could defer revenue, weaken customer experience, and require elevated capital spending. The pace and efficiency of expansion will influence whether strong demand converts into sustainable growth and margins.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $14.19 and its highest was $33.65 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $7.77B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Nov 11, 2026 which is in 32 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Aug 05, 2026. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.006.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of 2.06%. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,595,180 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went up 21.581%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$28.33 (1.15% Upside)
$28.33 (1.15% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 57%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 97.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $12.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.54%
12-Months-Change
Fundamentals
Return on Equity
18.77%
Trailing 12-Months
Asset Growth
28.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong operational and financial quarter with substantial year-over-year growth in revenue (+45%), molecular profiling (+55%), and clinical volume (+18%), alongside meaningful margin expansion (GAAP gross margin 68%) and sustained positive adjusted EBITDA and free cash flow. Major product launches (Caris Detect, ChromoSeq, MIClarity V2) and the company’s large proprietary dataset and AI capabilities were highlighted as durable competitive advantages. The primary negatives were operational scaling risks (capacity/backorders), regulatory/reimbursement uncertainty for MCED, MRD evidence-timing uncertainty, and a one-time $25M refinancing charge. Overall, the positives — robust growth, profitability, product launches, and a strong balance sheet — outweigh the manageable execution and timing risks.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$28.33
▲(1.15% Upside)
Technical Analysis
Bio-Techne
―
Veracyte
―
Adaptive Biotechnologies
―
Maravai Lifesciences Holdings
―
Recursion Pharmaceuticals
―
Ownership Overview
49.36% Insiders
16.19% Mutual Funds
0.27% Other Institutional Investors
25.47% Public Companies and
Individual Investors